Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJun112012	Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications San Diego, CA – Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. Read All »	View HTML Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and IPS Cell Culture Applications 11.3 KB
Toggle SummaryMay162018	Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular Read All »	View HTML
Toggle SummarySep072016	Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies Unite Cellular Immunotherapy Expertise to Accelerate Clinical Translation of Off-the-Shelf Products Offering Broad Patient Access Collaboration to Use Engineered Pluripotent Cell Lines to Renewably Generate T-Cell Product Candidates Foundational Intellectual Property Covering Pluripotent Read All »	View HTML Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies 19.2 KB
Toggle SummaryJul142015	Fate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies "Adaptive" Natural Killer Cell Therapeutics to be Advanced as Antibody-Mediated Cancer Therapy Genetically-Engineered Induced Pluripotent Stem Cell-derived Natural Killer Cells to be Developed as Off-the-Shelf Targeted Immunotherapy Fate Therapeutics Holds an Exclusive Option to Secure All Patent Read All »	View HTML Fate Therapeutics and Regents of the University of Minnesota Enter Into Research Collaboration for Translation of Natural Killer Cell Cancer Immunotherapies 23.9 KB
Toggle SummaryFeb272017	Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer First-of-Kind Product Candidate to be Manufactured from an Engineered Induced Pluripotent Stem Cell Line Intellectual Property Covering Compositions of Novel CD16 and Read All »	View HTML Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy 21.6 KB
Toggle SummaryDec062017	Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies Product Candidates to Incorporate Chimeric Antigen Receptor Construct Optimized for NK Cell Persistence and Anti-Tumor Activity Master Pluripotent Cell Lines Engineered with Chimeric Antigen Receptors to be used for Off-the-Shelf Targeted Natural Killer Cell Product Candidates SAN DIEGO, Dec. Read All »	View HTML Fate Therapeutics and University of California San Diego Launch Research Collaboration to Develop iPSC-Derived CAR NK Cell Cancer Immunotherapies 71.4 KB
Toggle SummaryAug082016	Fate Therapeutics Announces $10.3 Million Common Stock Private Placement SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a securities purchase agreement for a Read All »	View HTML Fate Therapeutics Announces $10.3 Million Common Stock Private Placement 38.3 KB
Toggle SummaryNov092021	Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference Company to Host Virtual Investor Event on Monday, November 15 SAN DIEGO , Nov. 09, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today Read All »	View HTML
Toggle SummaryMar192018	Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™ No Events of Cancer Relapse No ProTmune-related Serious Adverse Events Reported by Investigators SAN DIEGO , March 19, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for Read All »	View HTML
Toggle SummaryMay052020	Fate Therapeutics Announces Changes to its Board of Directors SAN DIEGO , May 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the retirement of Amir Nashat , Sc.D., Managing Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.